Capmatinib 150 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150 mg, 200 mg

Reference Brands: Tabrecta (USA/EU)

Category: Oncology Cancer Care

Capmatinib is a Oncology Cancer Care product available as Tablets in strengths 150 mg, 200 mg. It corresponds to the reference brand Tabrecta (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Capmatinib is a targeted anticancer medication used for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a specific genetic alteration known as MET exon 14 skipping mutation. It belongs to the class of kinase inhibitors and works by selectively blocking the MET receptor tyrosine kinase (also known as hepatocyte growth factor receptor, HGFR), which plays a key role in tumor cell growth, survival, and spread when abnormally activated. By inhibiting this pathway, capmatinib helps slow cancer progression and reduce tumor activity in patients with MET-driven disease.

Capmatinib is prescribed only after confirmed molecular testing shows the presence of the MET exon 14 skipping mutation, making it a precision therapy aligned with biomarker-based treatment selection. Clinical studies have demonstrated meaningful response rates and durable tumor control in eligible patients. The medicine is marketed under the brand name Tabrecta and is used under oncology specialist supervision, with regular monitoring for safety and treatment response. It represents an important personalized treatment option in modern lung cancer care.